Sorafenib: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

@@ Line 6: / Line 6: @@
 * Date of FDA Approval (Patent Expiration): 2005 (2020)<br />
 * 2009 Sales: ~$904 Million <ref>http://quicktake.morningstar.com/Stocknet/san.aspx?id=358559</ref>
-* Importance: Currently among the most effective Renal and Liver  [[pharma drugs|cancer treatments]] available. Sunitinib is the first treatment for renal cell carcinoma to demonstrate an overall survival of longer than two years. Has very impressive results with gastrointestinal stromal tumors.  It was the first [[cancer]] drug to be approved simultaneously for two different indications. Controversial due to its high cost of $38,000 per year.
+* Importance: Currently among the most effective Renal and Liver  [[pharma drugs|cancer treatments]] available. Part of the new tyrosine kinase inhibitor drug class. Has very impressive results with renal and liver [[cancer]], nearly doubling progression free survival compared to the palcebo group although without impacting quality of life measurements likely due to the relatively harsh side effect profile inherent to any multi kinase inhibitor.  Controversial due to its high cost of $70,000 per year.
 * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders.